Compositions and methods for detecting allogeneic matter in a subject

Patent metadata

Field	Value
Publication number	US-10604805-B2
Application number	US-201314382105-A
Country	US
Kind code	B2
Filing date	Mar 1, 2013
Priority date	Mar 1, 2012
Publication date	Mar 31, 2020
Grant date	Mar 31, 2020

Abstract

The present disclosure provides a panel of nucleic acid molecule primers specific for HLA-specific alleles and other genetic polymorphisms, which are useful for quantitatively amplifying these markers to detect, diagnose, and monitor individuals who have or are at risk of certain disease conditions, such as autoimmune disease, proliferative disease, infectious disease, allograft rejection, or pregnancy-related pathologies.

First claim

What is claimed is:

1. A composition, comprising a forward nucleic acid molecule, a reverse nucleic acid molecule, and a probe nucleic acid molecule that are complementary to a target nucleic acid molecule selected from:
(a) SE-HR, wherein the composition comprises a forward nucleic acid molecule having a length of up to 24 nucleotides and including the sequence as set forth in SEQ ID NO:58, a reverse nucleic acid molecule having a length of up to 27 nucleotides and including the sequence as set forth in SEQ ID NO:59 and a probe nucleic acid molecule consisting of a length of up to 14 nucleotides and includes the sequence as set forth in SEQ ID NO:60; or
(b) SE-HR, wherein the composition comprises a forward nucleic acid molecule having a length of up to 24 nucleotides and including the sequence as set forth in SEQ ID NO:61, a reverse nucleic acid molecule having a length of up to 27 nucleotides and including the sequence as set forth in SEQ ID NO:62 and a probe nucleic acid molecule consisting of a nucleic acid sequence, a fluorophore and a quencher, wherein the nucleic acid sequence has a length of up to 14 nucleotides and includes the sequence as set forth in SEQ ID NO:63.

2. A composition comprising a forward nucleic acid molecule, a reverse nucleic acid molecule, and a probe nucleic acid molecule, wherein the forward, reverse and probe nucleic acid molecules are complementary to SE-HR, and wherein (a) the forward nucleic acid molecule has a length of up to 24 nucleotides and includes the sequence as set forth in SEQ ID NO:58, or consists of the sequence as set forth in SEQ ID NO:58, the reverse nucleic acid molecule has a length of up to 27 nucleotides and includes the sequence as set forth in SEQ ID NO:59, or consists of the sequence as set forth in SEQ ID NO:59, and the probe nucleic acid molecule consists of a nucleic acid sequence, a fluorophore and a quencher, wherein the nucleic acid sequence has a length of up to 14 nucleotides and includes the sequence as set forth in SEQ ID NO:60 or the nucleic acid sequence consists of the sequence as set forth in SEQ ID NO:60; or (b) the forward nucleic acid molecule has a length of up to 24 nucleotides and includes the sequence as set forth in SEQ ID NO:61, or consists of the sequence as set forth in SEQ ID NO:61, the reverse nucleic acid molecule has a length of up to 27 nucleotides and includes the sequence as set forth in SEQ ID NO:62, or consists of the sequence as set forth in SEQ ID NO:62, and the probe nucleic acid molecule consists of a nucleic acid sequence, a fluorophore and a quencher, wherein the nucleic acid sequence has a length of up to 14 nucleotides and includes the sequence as set forth in SEQ ID NO:63 or the nucleic acid sequence consists of the sequence as set forth in SEQ ID NO:63.

3. The composition according to claim 2 , further comprising an inhibitor nucleic acid molecule having a length of up to 24 nucleotides and including the sequence as set forth in SEQ ID NO:85, or an inhibitor nucleic acid molecule consisting of the sequence as set forth in SEQ ID NO:85.

4. The composition according to claim 1 , wherein the fluorophore is located at the 5′-end of the probe nucleic acid molecule and the quencher is located at the 3′-end of the probe nucleic acid molecule.

5. The composition of claim 4 wherein the fluorophore is FAM and the quencher is TAMRA or BHQ.

6. The composition of claim 4 wherein at least one nucleotide of the probe is a duplex stabilizer.

7. The composition of claim 6 wherein the duplex stabilizer is at least one LNA or MGB.

8. A process for detecting microchimerism, comprising:
(a) amplifying target nucleic acid molecules of a test biological sample using one or more nucleic acid compositions according to claim 1 , wherein the biological sample comprises a known HLA genotype;
(b) amplifying nucleic acid molecules of a control biological sample using the one or more nucleic acid molecule compositions of (a), wherein the control biological sample comprises a known HLA genotype that is different from the test biological sample; and
(c) detecting the presence of microchimerism when the presence of certain HLA markers amplified in the test biological sample indicates the presence of microchimerism, wherein the certain HLA markers amplified are not identified in the HLA genotype of the test biological sample and are identified in HLA genotype of the control biological sample.

9. The method of claim 8 , wherein the detection sensitivity is 1 chimeric genome in 10 5 host genomes.

10. A method for detecting incipient allograft rejection, comprising:
(a) obtaining a first biological sample from a subject prior to receiving a transplant from a transplant donor and a second biological from the same subject after receiving the transplant during a period of time when there is a risk of rejection;
(b) amplifying target nucleic acid molecules from the biological samples using one or more nucleic acid compositions according to claim 1 , wherein one or more of the nucleic acid compositions comprising the forward, the reverse, and the probe nucleic acid molecules are complementary to target nucleic acid molecules found in the transplant donor and not found in the transplant recipient; and
(c) detecting incipient allograft rejection in the transplant recipient when the presence of amplified target nucleic acid molecules from the transplant donor are detected in the transplant recipient.

11. The method of claim 10 , wherein the biological sample is blood or serum.

12. The method of claim 10 , wherein the transplant comprises a kidney transplant, a pancreas transplant, an islet cell transplant, a hematopoietic cell transplant, a cord blood transplant or a bone marrow transplant.

13. The method of claim 8 , wherein the microchimerism detected is maternal microchimerism or fetal microchimerism.

Assignees

• Hutchinson Fred Cancer Res

Inventors

• Nelson J Lee
• Lambert Nathalie C
• Gadi Vijayakrishna K
• Yan Zhen

Classifications

• C12Q2600/158

  Expression markers · CPC title

• C12Q1/6881 Primary

  for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes · CPC title

• C12Q1/6883

  for diseases caused by alterations of genetic material · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title